Skip to main content

PRECISION ONCOLOGY CONGRESS

NOVEMBER 7 & 8, 2024

POET CHAIRS

Pinaki Bose, Ph.D

Assistant Professor, Departments of Biochemistry & Molecular Biology and Oncology
University of Calgary
Director, Tumour Biology and Translational Research, Ohlson Research Initiative
Arnie Charbonneau Cancer Institute
Calgary, AB

Dr. Pinaki Bose completed his Ph.D. with Dr. Karl Riabowol at the University of Calgary, investigating the role of the ING1 tumour suppressor protein in DNA damage signaling and apoptosis. After completing his Ph.D., Pinaki joined the Ohlson Research Initiative (ORI) as a postdoctoral fellow and trained in the molecular epidemiology of head and neck cancers under the supervision of Drs. Joseph Dort and Nigel Brockton. As part of a second postdoctoral fellowship, Pinaki trained at the BC Cancer Agency (BCCA) Genome Sciences Centre in cancer genomics and bioinformatics under one of the leading bioinformaticians in the world, Dr. Steven Jones. Pinaki was also a member of the personalized oncogenomics (POG) program at BC Cancer. The POG initiative administers genome-guided targeted therapies to recurrent/metastatic cancer patients.

Dr. Bose currently directs the translational research program within the ORI, a multidisciplinary head and neck cancer research initiative. The Bose lab investigates the biology of head and neck, brain and lung cancers focusing on the role of the immune system in carcinogenesis and progression.

Steven Yip MD, MSc, FRCPC

Medical Oncologist
Medical Lead, Precision Oncology and Experimental Therapeutics
Chair, Southern Alberta GU Tumour Group
Clinical Assistant Professor
Department of Oncology, Cumming School of Medicine
Tom Baker Cancer Centre
Calgary, AB

Dr. Steven Yip is a Staff Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. He is the Southern Alberta GU Tumour Group Chair, Medical Lead of Precision Oncology and Experimental Therapeutics (POET), and Southern Alberta Prostate Cancer Research Institute (APCaRI) Co-Chair. He is a Clinical Assistant Professor of Medicine at the University of Calgary. He has an academic focus on translational research, PSMA PET/CT imaging and novel radiopharmaceutical drug development in advanced prostate cancer. He completed his medical oncology clinical and translational research genitourinary fellowship, under the supervision of Dr. Kim Chi at BC Cancer. He received his MD at the University of Alberta and trained at the University of British Columbia and the University of Calgary. He has a Masters of Science in Health Research Methodology from McMaster University.

Key Publications: 

Reimers MA, Yip SM (Co-First Authors), Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2019. In Press.

Yip SM, Wells C, Moreira RB, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst S, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Soulieres D, Canil CM, Kapoor A, Fu SY, Choueiri TK, Heng DYC. Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma Patients (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Cancer. 2018;124(18):3677-83.

Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A,Yip SM, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E, Saad F, Iqbal N, Nykter Matti, Gleave ME, Wang Y, Annala M, Chi KN, and Wyatt AW. Activating AKT1 and PIK3CA mutation in metastatic castration-resistant prostate cancer. Eur Urol. 2020. https://doi.org/10.1016/j.eururo.2020.04.058

Jette N, Kumar M, Radhamani S, Arthur G, Goutam S, Yip SM, Kolinsky M, Williams G,

Bose P, Lees-Miller S. ATM-deficient cancers provide new opportunities for precision oncology. Cancers. Cancers (Basel). 2020 Mar 14;12(3). pii: E687. doi: 10.3390/cancers12030687

Yip SM, Loewen SK, Li H, Hao D, Easaw JC. Management of Medical Oncology Services in Canada: Redefined Workload with a Novel Supply-and-Demand Workforce Projection Model. J Oncol Pract. 2018;14(7):e438-e445.

Yip SM, Kaiser J, Li H, North S, Heng DY, Alimohamed NS. Real World Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. Clin Genitourin Cancer. 2018;16(3):e637-e644.

Yip SM, Ruiz Morales J, Donskov F, Fraccon A, Umberto B, Rini BI, Lee JL, Bjarnason G, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC. Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer J.2017;1(1):41-47.

POET FACULTY

Peter Campbell

Head of Cancer, Ageing and Somatic Mutation,
Senior Group Leader,
Wellcome Sanger Institute
Hinxton, England

Dr Peter Campbell is Head of the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute, having started a Wellcome Senior Clinical Fellowship in 2010. He completed specialist training in Haematology in New Zealand and Australia in 2002. Following this, he completed a PhD at the University of Cambridge in the molecular pathogenesis of myeloproliferative disorders. Since 2007, Dr Campbell has been employed at the Cancer Genome Project, Wellcome Trust Sanger Institute.

His major interest is cancer genomics, and in particular genome-wide analyses of somatic mutations in tumours. The four major areas of interest have been:

  • the discovery of new cancer genes;
  • the identification of somatic mutation processes operative in tumours;
  • the characterisation of patterns of cancer evolution; and
  • the translation of these fundamental insights about cancer biology into better management of patients.

Further details are available at: http://www.sanger.ac.uk/people/directory/campbell-peter

Tim Halim

Group Leader, University of Cambridge
Cancer Research UK – Cambridge Institute
Cambridge, UK

Tim Halim is a group leader at the University of Cambridge, Cancer Research UK – Cambridge Institute. He did his PhD training in the laboratory of Prof. Fumio Takei at the University of British Columbia (Vancouver, Canada), followed by a postdoc with Dr. Andrew McKenzie at the MRC Laboratory of Molecular Biology (Cambridge, UK). He contributed to the characterization of ILC2 in the airways, and their role in promoting allergic inflammation by engaging both innate and adaptive arms of the immune system. His laboratory continues investigating the cellular and molecular interactions whereby ILC2 locally regulate different aspects of the immune response in cancer, tissue homeostasis and inflammatory diseases. Besides CRUK funding, Tim has been supported by CIHR Banting postdoctoral and Wellcome Sir Henry Dale independent research fellowships.

https://www.cruk.cam.ac.uk/research-groups/halim-group/

David Huntsman, MD, FRCPC, FCCMG

Professor, Departments of Pathology and Laboratory Medicine, Obstetrics & Gynaecology,
University of British Columbia
Canada Research Chair, Molecular and Genomic Pathology
Director, OVCARE
BC Cancer
Vancouver, BC

Dr. David Huntsman, a pathologist and clinical molecular geneticist at the University of British Columbia is the Canada Research Chair in Molecular and Genomic Pathology. Dr. Huntsman directs OVCARE, BC’s multidisciplinary ovarian cancer research team and conducts his research at the BC Cancer Agency and the Vancouver General Hospital. Dr. Huntsman’s research has led to development of diagnostic, predictive and prognostic tissue based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for subtype specific ovarian cancer control and have been leaders in the application of novel genomic technologies to better prevent, diagnose and treat ovarian cancer. Dr. Huntsman is a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

Nicholas Jacquelot, MSc., PhD.

Cumming School of Medicine,
University of Calgary
Calgary, AB

Dr. Nicolas Jacquelot completed his PhD in Cancer Immunology in the laboratory of Professor Laurence Zitvogel at Gustave Roussy Institute. He pursued his postdoctoral training in Professor Gabrielle Belz’s group at The Walter and Eliza Hall Institute of Medical Research and in Professor Pamela Ohashi’s laboratory at the Princess Margaret Cancer Centre. In January 2023, he opened his laboratory at the University of Calgary in the Cumming School of Medicine.

Dr. Jacquelot’s laboratory is studying the role and function of the immune system in cancer. We examine the contribution of the innate lymphoid cells (ILCs) to tumor development and therapy responses. Ongoing research efforts include (i) investigating the cellular and molecular pathways influencing ILC function in tumors, (ii) dissecting ILC signaling pathways and communication with other cells within the tumor microenvironment, and (iii) determining ILC prognostic values and therapeutic potential in cancer. Our overreaching goal is to improve cancer patient prognosis through the development of ILC-based treatments.

Trevor Pugh, PhD, FACMG

Canada Research Chair in Translational Genomics
Senior Scientist, Princess Margaret Cancer Centre
Director, Genomics, Ontario Institute for Cancer Research
Professor, Department of Medical Biophysics, University of Toronto
Toronto, ON

Dr. Trevor Pugh, PhD, FACMG is a cancer genomics researcher, board-certified molecular geneticist, and holder of the Canada Research Chair in Translational Genomics. He is appointed as Professor in the University of Toronto Department of Medical Biophysics, Senior Scientist at the Princess Margaret Cancer Centre, and Senior Investigator at the Ontario Institute for Cancer Research. He is Director of the OICR Genomics Program and the Princess Margaret Genomics Centre, genomics cores that specialize in single cell, cell-free DNA and clinically-accredited whole genome sequencing. He has contributed to multiple large-scale genomics and data-sharing programs including NCI TARGET, AACR GENIE, and the Terry Fox Marathon of Hope Cancer Centres Network. Most recently, he was recognized by Canada’s Top 40 Under 40, the Canadian Cancer Society Bernard and Francine Dorval Prize, and the Allan Slaight Collaborator of the Year Award. He leads the national CHARM Consortium, an initiative to use cell-free DNA monitoring for all people with an inherited predisposition to cancer.

Christian Steidl, MD

Research Director, Centre for Lymphoid Cancer
Senior Executive Director Research, BC Cancer
Professor, Department of Pathology and Laboratory Medicine,
University of British Columbia,
Vancouver, BC

Dr Steidl is the Research Director of the Centre for Lymphoid Cancer, Senior Executive Director Research at BC Cancer and Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. He has expertise in clinical malignant hematology, molecular pathology, genomics and lymphoma biology. Dr Steidl’s translational research group focuses on the pathogenesis of B cell lymphomas, tumor microenvironment biology and applied genomics. He is most known for his discovery and characterization of novel gene mutations and microenvironment-related biomarkers in Hodgkin and Non-Hodgkin lymphomas. Dr Steidl is lead investigator of a team grant on modeling lymphoma evolution and clinical trajectory using multiomics funded by the Terry Fox Research Institute (TFRI), and project leader of a Genome Canada Large-Scale Applied Research Project to advance personalized treatments of lymphoid cancer patients. Dr Steidl is a member of the Scientific Advisory Board of the Lymphoma Research Foundation, past Chair of the American Society of Hematology Scientific Committee on Lymphoid Neoplasia and Member of the Leukemia and Lymphoma Society of Canada Medical and Scientific Advisory Committee. He was inducted as a member of the Royal Society of Canada, College for New Scholars, Artists and Scientists in 2017, and won an Allen Distinguished Investigator award in 2018.

Logan Walsh, Ph.D.

Associate Professor, Goodman Cancer Institute & Department of Human Genetics
McGill University
Rosalind Goodman Chair, Lung Cancer Research
Montreal, QC

Dr. Walsh is an Associate Professor at the Goodman Cancer Institute and Department of Human Genetics at McGill University. He currently holds the Rosalind Goodman Chair in Lung Cancer Research. Dr. Walsh’s lab uses spatial proteomics combined with artificial intelligence to help develop personalized medicine strategies for cancer patients. In his talk, he will be describing some of his more recent work in understanding the tumour immune microenvironment and how we can leverage spatial information to better understand cancer progression and response to therapy.

Alex Wyatt, DPhil

Associate Professor, University of British Columbia
Senior Research Scientist, Vancouver Prostate Centre
Senior Scientist, Michael Smith Genome Sciences Centre, BC Cancer
Vancouver, BC

Dr. Wyatt is an associate professor in Urologic Sciences at the University of British Columbia, Canada. He is a senior research scientist at the Vancouver Prostate Centre and a senior scientist at BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford.

His research goals are to identify associations between genomic alterations and patient outcomes in metastatic prostate and bladder cancer, and to translate these findings into clinical biomarkers.

Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response.

Dr. Wyatt is the chair of correlative sciences and tumour biobanking for the Canadian Cancer Trial Group (CCTG) and through this role is involved in design and execution of phase I-III clinical trial protocols across Canada. Dr. Wyatt directs the ctDNA screening strategy and the molecular tumor board for the first multi-center phase 2 umbrella trial in metastatic castration-resistant prostate cancer (NCT03385655, NCT02905318).